-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the accelerating aging of Chinese society, the proportion of patients with cardiovascular and cerebrovascular diseases has become higher and higher, and the demand for treatment of cardiovascular and cerebrovascular diseases and drugs has begun to increase year by year
.
Statistics show that in 2020, there will be 21 cardio-cerebrovascular Chinese patent medicines with sales exceeding 1 billion yuan, and the total sales scale will exceed 40 billion yuan
.
With the continuous increase in the number of patients with cardiovascular and cerebrovascular diseases, relevant departments in China have begun to pay more and more attention to the prevention and control of cardiovascular and cerebrovascular diseases
.
In the "Healthy China Action (2019-2030)", specific instructions were made on the prevention and treatment of cardiovascular and cerebrovascular diseases, and it was clearly necessary to promote the "three highs" co-management to carry out overweight and obesity, increased blood pressure and blood sugar, and dyslipidemia and other high-risk groups.
Disease risk assessment and intervention guidance, and standardized management of hypertension, diabetes, and dyslipidemia
.
In addition, in the "Guiding Opinions on Establishing and Improving the Employee Basic Medical Insurance Outpatient Mutual Aid Guarantee Mechanism (Draft for Comment)" issued by the National Medical Insurance Administration last year, it was also mentioned that the outpatient mutual aid guarantee function should be strengthened
.
Starting with chronic diseases such as hypertension and diabetes, which are burdened by the masses, the general outpatient medical expenses for frequently-occurring and common diseases are gradually included in the scope of the overall planning fund
.
It is worth noting that under the influence of a series of favorable policies and the rapidly increasing number of patients with cardiovascular and cerebrovascular diseases, related drugs have begun to usher in a huge market space
.
According to statistics, the market size of China's cardiovascular and cerebrovascular disease drugs has increased from 144.
4 billion yuan in 2014 to 206 billion yuan in 2018, and is expected to reach 286.
3 billion yuan in 2023, with a compound annual growth rate of 6.
8% from 2018 to 2023
.
The industry predicts that with China’s increasingly aging population, continuous advancement of medical reforms, and continuous research and development of independent original research drugs, China’s cardiovascular disease drugs will have strong competitiveness, and the entire industry will maintain double-digit growth
.
With the continuous expansion of the market, it is expected that more and more companies will increase their deployment in this field and continue to benefit more patients in the future
.
It is understood that in fact, Tencent invested 300 million yuan recently to lead an investment in a smart medical company for cardiovascular and cerebrovascular diseases.
.
Specifically, in November Ruixin Medical officially announced the completion of the B round of nearly 300 million yuan in financing
.
This round of financing was led by Tencent, followed by Matrix Partners China, and China Renaissance Capital served as the exclusive financial advisor for this financing
.
After this round of financing, Ruixin Medical will be committed to the large-scale commercial promotion of Ruixin-FFR, strengthen the overall research and development of the cardio-cerebral vascular intelligence platform, and work with partners to promote product admissions to help medical workers optimize the diagnosis and treatment process and realize the heart Non-invasive and accurate diagnosis of cerebrovascular diseases
.
The analysis believes that China has achieved a lot of results in the management and control of hypertension and diabetes; and with the continuous emergence of related drugs, patients have more and more better choices in drug selection
.
But from the screening point of view, treatment and management are still weak
.
Among them, the public's insufficient attention to blood lipid control is a major shortcoming of cardiovascular prevention
.
Therefore, in order to better control the cardiovascular and cerebrovascular market, it is necessary to promote the full-process management of chronic diseases and carry out early intervention
.
In addition, in terms of treatment, pharmaceutical companies also need to focus on the clinical value of innovative drugs and continue to meet the medication needs of patients with cardiovascular diseases
.
.
Statistics show that in 2020, there will be 21 cardio-cerebrovascular Chinese patent medicines with sales exceeding 1 billion yuan, and the total sales scale will exceed 40 billion yuan
.
With the continuous increase in the number of patients with cardiovascular and cerebrovascular diseases, relevant departments in China have begun to pay more and more attention to the prevention and control of cardiovascular and cerebrovascular diseases
.
In the "Healthy China Action (2019-2030)", specific instructions were made on the prevention and treatment of cardiovascular and cerebrovascular diseases, and it was clearly necessary to promote the "three highs" co-management to carry out overweight and obesity, increased blood pressure and blood sugar, and dyslipidemia and other high-risk groups.
Disease risk assessment and intervention guidance, and standardized management of hypertension, diabetes, and dyslipidemia
.
In addition, in the "Guiding Opinions on Establishing and Improving the Employee Basic Medical Insurance Outpatient Mutual Aid Guarantee Mechanism (Draft for Comment)" issued by the National Medical Insurance Administration last year, it was also mentioned that the outpatient mutual aid guarantee function should be strengthened
.
Starting with chronic diseases such as hypertension and diabetes, which are burdened by the masses, the general outpatient medical expenses for frequently-occurring and common diseases are gradually included in the scope of the overall planning fund
.
It is worth noting that under the influence of a series of favorable policies and the rapidly increasing number of patients with cardiovascular and cerebrovascular diseases, related drugs have begun to usher in a huge market space
.
According to statistics, the market size of China's cardiovascular and cerebrovascular disease drugs has increased from 144.
4 billion yuan in 2014 to 206 billion yuan in 2018, and is expected to reach 286.
3 billion yuan in 2023, with a compound annual growth rate of 6.
8% from 2018 to 2023
.
The industry predicts that with China’s increasingly aging population, continuous advancement of medical reforms, and continuous research and development of independent original research drugs, China’s cardiovascular disease drugs will have strong competitiveness, and the entire industry will maintain double-digit growth
.
With the continuous expansion of the market, it is expected that more and more companies will increase their deployment in this field and continue to benefit more patients in the future
.
It is understood that in fact, Tencent invested 300 million yuan recently to lead an investment in a smart medical company for cardiovascular and cerebrovascular diseases.
.
Specifically, in November Ruixin Medical officially announced the completion of the B round of nearly 300 million yuan in financing
.
This round of financing was led by Tencent, followed by Matrix Partners China, and China Renaissance Capital served as the exclusive financial advisor for this financing
.
After this round of financing, Ruixin Medical will be committed to the large-scale commercial promotion of Ruixin-FFR, strengthen the overall research and development of the cardio-cerebral vascular intelligence platform, and work with partners to promote product admissions to help medical workers optimize the diagnosis and treatment process and realize the heart Non-invasive and accurate diagnosis of cerebrovascular diseases
.
The analysis believes that China has achieved a lot of results in the management and control of hypertension and diabetes; and with the continuous emergence of related drugs, patients have more and more better choices in drug selection
.
But from the screening point of view, treatment and management are still weak
.
Among them, the public's insufficient attention to blood lipid control is a major shortcoming of cardiovascular prevention
.
Therefore, in order to better control the cardiovascular and cerebrovascular market, it is necessary to promote the full-process management of chronic diseases and carry out early intervention
.
In addition, in terms of treatment, pharmaceutical companies also need to focus on the clinical value of innovative drugs and continue to meet the medication needs of patients with cardiovascular diseases
.
